Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 33Ovarian Neoplasms 9Breast Neoplasms 9Pancreatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Castration-Resistant Prostate Carcinoma 2Xanthogranuloma, Juvenile 1

Interventions

Early Intervention, Educational 2olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate × olaparib × Genitourinary × Clear all
NCT03047135 2026-05-12

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
51 enrolled 8 charts
Genitourinary

Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡